Company Overview and News

6
GEN / Genesis Healthcare, Inc. 8-K (Current Report)

2018-10-03 sec.gov - 6
gen_Current folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
GEN

3
Genesis HealthCare Announces Completed Divestiture of 16 Facilities in Texas

2018-10-02 globenewswire - 3
KENNETT SQUARE, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN), one of the largest post-acute care providers in the United States, today announced it completed the sale of 15 owned skilled nursing facilities and exited the operations of one leased skilled nursing facility located in Texas. Genesis previously exited the operations of one additional leased facility, leaving seven remaining skilled nursing facilities under operation in Texas, which are expected to be sold in the fourth quarter of 2018.
DTK GEN

2
The Healthiest Healthcare REITs

2018-08-17 seekingalpha - 2
The core business of healthcare is inherently driven by demand for patient care, providing a stable foundation to support investment in the sector.
VTR GEN

 
GEN / Genesis Healthcare, Inc. 10-Q (Quarterly Report)

2018-08-09 sec.gov
gen_Current folio_10Q Table of Contents
GEN

 
Genesis Healthcare, Inc. (GEN) CEO George Hager on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning. My name is Tom and I will be your conference operator today. At this time, I would like to welcome everyone to the Genesis Healthcare Second Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks there will be a question-and-answer session. [Operator Instructions].
GEN

2
Genesis Healthcare (GEN) Reports Q2 Loss, Lags Revenue Estimates

2018-08-08 zacks - 1
Genesis Healthcare (GEN - Free Report) just came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
KRO CIVI GEN SBOW

 
GEN / Genesis Healthcare, Inc. 8-K (Current Report)

2018-08-08 sec.gov
gen_current folio_8K_Earnings UNITED STATES SECURITIES AND EXCHANGE COMMISSION
GEN

 
GEN / Genesis Healthcare, Inc. 8-K (Current Report)

2018-07-31 sec.gov
gen_Current folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
GEN

1
Genesis HealthCare Expects to Release Second Quarter 2018 Results on August 7, 2018

2018-07-23 globenewswire - 1
KENNETT SQUARE, Pa., July 23, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (NYSE:GEN) (Genesis or the Company), one of the nation’s largest providers of post-acute care, today announced that it expects to release its second quarter 2018 results after the market closes on Tuesday, August 7, 2018. A conference call and webcast will be held on Wednesday, August 8, 2018 at 8:30 a.m. Eastern Time to discuss the results.
GEN

 
It's Easy To Be Patient With This 8% Dividend

2018-07-18 seekingalpha
Sabra Healthcare might be one of the few healthcare REITs that is currently a net acquirer of assets.
GEN CCP

 
Home DNA testing gains popularity in aging Japan

2018-07-18 japantimes.co.jp
DNA testing at home is starting to gain traction nationwide as more people age and seek answers about their risks for diseases.
GEN RKUNY RKUNF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to GEN / Genesis Healthcare, Inc. on message board site Silicon Investor.

Robotics and Artificial Intelligence Robotics and Artificial Intelligence Robotics and Artificial Intelligence Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit
Regeneron Pharmaceuticals Regeneron Pharmaceuticals Regeneron Pharmaceuticals General Electric (GE) General Electric (GE) General Electric (GE)
Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera Silicon Investor - User Site Discussion - Generally Unmodera GENI: GenesisIntermedia.com Inc GENI: GenesisIntermedia.com Inc GENI: GenesisIntermedia.com Inc
Genealogy Genealogy Genealogy General market lab and commentary General market lab and commentary General market lab and commentary
MGNX -- MacroGenics MGNX -- MacroGenics MGNX -- MacroGenics ImmunoGen ImmunoGen ImmunoGen